
Opinion|Videos|June 24, 2024
Recent Data from COMMIT in dMMR/MSI-High Metastatic Colorectal Cancer
Mark A. Lewis, MD, discusses recent data from the COMMIT trial investigating first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
2
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
3
FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5



















